SKB-315

N/A

Report date: 2026/05/19 16:25:43

Base Information

Drug NameSKB-315
Drug Alias Name注射用SKB315SKB-315SKB315MK1200MK-1200
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-CLDN18DNA topoisomerase I inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsClaudin-18 splice variant 2DNA topoisomerase I
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesPoland +[11] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSichuan Kelun-Biotech Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesMerck Sharp & Dohme CorpMerck Sharp & Dohme LLCSichuan Kelun-Biotech Biopharmaceutical Co Ltd
Inactive CompaniesMSD R&D（China）Co Ltd
Active IndicationsGastroesophageal Junction NeoplasmsSolid tumoursStomach Neoplasms +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A